Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulrik Ø Andersen in
Google Scholar
PubMed
Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Dijana Terzic in
Google Scholar
PubMed
Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Centre for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Nicolai Jacob Wewer Albrechtsen in
Google Scholar
PubMed
Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Peter Dall Mark in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Peter Plomgaard in
Google Scholar
PubMed
Search for other papers by Jens F Rehfeld in
Google Scholar
PubMed
Search for other papers by Finn Gustafsson in
Google Scholar
PubMed
Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens P Goetze in
Google Scholar
PubMed
. The drug is composed of valsartan, an angiotensin-II receptor 1 blocker, and sacubitril, which inhibits the peptide-degrading enzyme neprilysin (neutral endopeptidase 24.11) ( 1 ). Neprilysin degrades a plethora of peptide hormones, including atrial
Search for other papers by Hugo R Ramos in
Google Scholar
PubMed
Department of Internal Medicine, Section of Metabolic Vascular Medicine, Division of Diabetes and Nutritional Sciences, Cardiovascular Endocrinology Laboratory, Faculty of Medicine, Hospital de Urgencias, National University of Córdoba, X5000 Córdoba, Argentina
Search for other papers by Andreas L Birkenfeld in
Google Scholar
PubMed
Search for other papers by Adolfo J de Bold in
Google Scholar
PubMed
strikingly low levels of plasma cNP (19, 20, 21, 22) due to multiple mechanisms that might include increased neprilysin-neutral endopeptidase activity resulting in increased degradation of circulating cNP and increased adipose tissue expression of the NP
Search for other papers by Justyna Modrzynska in
Google Scholar
PubMed
Search for other papers by Christine F Klein in
Google Scholar
PubMed
Search for other papers by Kasper Iversen in
Google Scholar
PubMed
Search for other papers by Henning Bundgaard in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Bolette Hartmann in
Google Scholar
PubMed
Search for other papers by Maike Mose in
Google Scholar
PubMed
Search for other papers by Nikolaj Rittig in
Google Scholar
PubMed
Search for other papers by Niels Møller in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Nicolai J Wewer Albrechtsen in
Google Scholar
PubMed
patients ( 13 ), in mice following LPS injection ( 23 ), and in humans with burn lesions ( 24 ). Estimation of plasma GLP-1 in mice is troublesome due to the rapid degradation by neprilysin ( 25 , 26 ), and the assays employed in the current human study
Search for other papers by Sara Ullsten in
Google Scholar
PubMed
Search for other papers by Sara Bohman in
Google Scholar
PubMed
Search for other papers by Marie E Oskarsson in
Google Scholar
PubMed
Search for other papers by K Peter R Nilsson in
Google Scholar
PubMed
Search for other papers by Gunilla T Westermark in
Google Scholar
PubMed
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Search for other papers by Per-Ola Carlsson in
Google Scholar
PubMed
microspheres ( n = 6, Fig. 4C , D and E ). There was neither any difference in the expression of insulin-degrading enzyme (IDE) ( n = 6, fold change 1.54 ± 0.51 in islets with microspheres) and neprilysin ( n = 4, fold change 1.22 ± 0.67 in islets with
Search for other papers by Xianghe Chen in
Google Scholar
PubMed
Search for other papers by Xinyu Zeng in
Google Scholar
PubMed
Search for other papers by Xiao Qiu in
Google Scholar
PubMed
Search for other papers by Chi Liu in
Google Scholar
PubMed
Search for other papers by Pengcheng Lu in
Google Scholar
PubMed
Search for other papers by Ziming Shen in
Google Scholar
PubMed
Search for other papers by Xiangxiang Zhou in
Google Scholar
PubMed
Search for other papers by Kang Yang in
Google Scholar
PubMed
Pressure Research 2021 46 219 – 228 . ( https://doi.org/10.1159/000514680 ) 27 Gutta S Grobe N Kumbaji M Osman H Saklayen M Li G & Elased KM . Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2